EPS for AstraZeneca plc (ADR) (AZN) Expected At $0.44

July 18, 2017 - By Hazel Jackson

 EPS for AstraZeneca plc (ADR) (AZN) Expected At $0.44

Investors wait AstraZeneca plc (ADR) (NYSE:AZN) to report on July, 27. its quarterly earnings Wall Street analysts expect $0.44 EPS, down $0.39 or 46.99 % from last year’s $0.83 same quarter earnings. This translates into $1.11B profit for AZN giving the stock a 18.97 P/E. This is assuming the current $0.44 EPS is accurate. AstraZeneca plc (ADR)’s Wall Street analysts see -55.56 % negative EPS growth, taking into account the $0.99 EPS reproted in the previous quarter, The stock decreased 1.45% or $0.49 during the last trading session, reaching $33.38. About 4.22M shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since July 18, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Among 19 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. AstraZeneca plc (ADR) had 27 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, February 26 by Cantor Fitzgerald. On Wednesday, April 5 the stock rating was downgraded by UBS to “Neutral”. The firm earned “Buy” rating on Monday, August 29 by Argus Research. On Wednesday, September 14 the stock rating was downgraded by BNP Paribas to “Neutral”. The rating was initiated by Piperjaffray with “Overweight” on Friday, September 23. The firm has “Buy” rating by Jefferies given on Monday, September 12. The firm has “Neutral” rating given on Monday, May 15 by Credit Suisse. Leerink Swann maintained AstraZeneca plc (ADR) (NYSE:AZN) rating on Monday, May 2. Leerink Swann has “Market Perform” rating and $34 target. On Monday, February 8 the stock rating was downgraded by HBSC to “Hold”. The firm earned “Underperform” rating on Tuesday, October 20 by Credit Suisse.

AstraZeneca PLC is a biopharmaceutical company. The company has market cap of $84.34 billion. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 24.93 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

More recent AstraZeneca plc (ADR) (NYSE:AZN) news were published by: Benzinga.com which released: “Fast Money Traders Share Their Picks That Could Make A Strong Move Higher” on July 17, 2017. Also Investorplace.com published the news titled: “Why Cyberark Software Ltd (CYBR), Teva Pharmaceutical Industries Ltd (ADR …” on July 14, 2017. Benzinga.com‘s news article titled: “Analyst Wonders If AstraZeneca’s CEO Would Be A Fit At Teva” with publication date: July 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.